Basic Information
| LncRNA/CircRNA Name | MALAT1 |
| Synonyms | NA |
| Region | GRCh38_11:65497688-65506516 |
| Ensemble | ENSG00000251562 |
| Refseq | NR_002819 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | Cisplatin | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | bladder cancer |
| ICD-0-3 | C67 |
| Methods | qPCR, Western blot, Luciferase reporter assay, RNAi |
| Sample | Human bladder epithelial immortalized cells SVHUC-1 and BC cell lines 5637, EJ-M3 and T24, BC tissues, the normal adjacent tissues |
| Expression Pattern | up-regulated |
| Function Description | MALAT1 expression was up-regulated in the BC tissues compared to the normal adjacent tissues and elevated in the cancer cells compared to the epithelial immortalized cells. Secondly, we found that suppression of MALAT1 enhanced the chemotherapeutic drug sensitivity and inhibited the cisplatin resistance of the BC cells. Thirdly, we showed that MALAT1 affected the cisplatin resistance of the BC cells via regulating the miR-101- 3p/VEGF-C pathway. |
| Pubmed ID | 31650173 |
| Year | 2019 |
| Title | LncRNA-MALAT1 mediates cisplatin resistance via miR-101-3p/VEGF-C pathway in bladder cancer |
External Links
| Links for MALAT1 | GenBank HGNC NONCODE |
| Links for bladder cancer | OMIM COSMIC |